Inhalation CDMO Market : Technology Advancements, Industry Insights, Trends And Forecast 2033

Overview and Scope

An inhalation contract development and manufacturing organization (CDMO) is a specialized organization that provides comprehensive services to pharmaceutical and biotechnology firms for the development and manufacturing of inhalable drugs. These organizations offer a range of services tailored specifically to the needs of inhalation products, including formulation development, analytical testing, process optimization, scale-up, and commercial manufacturing.

Sizing and Forecast

The inhalation CDMO market size has grown strongly in recent years. It will grow from $1.94 billion in 2023 to $2.08 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to rising prevalence of respiratory disorders, growing demand for personalized medicine, increasing outsourcing by pharmaceutical companies, growth of the biopharmaceutical industry.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report

Segmentation & Regional Insights

The inhalation cdmo market covered in this report is segmented –

1) By Product: Dry Powder Inhaler (DPIs), Metered Dose Inhaler (MDIs), Nebulizer, Soft Mist Inhaler

2) By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Acute Respiratory Distress Syndrome, Pulmonary Fibrosis

3) By Technology: Manual Inhalers (SMI), Digital Inhalers

4) By End-User: Big Pharmaceutical Companies, Small and Medium-sized Pharmaceutical Companies, Generic Pharmaceutical Companies, Other End-Users

North America was the largest region in the inhalation contract development and manufacturing organization (CDMO) market in 2023. The regions covered in the inhalation cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13864&type=smp

Major Driver Impacting Market Growth

The increasing prevalence of respiratory disorders is expected to propel the growth of the inhalation CDMO market going forward. Respiratory disorders are a group of medical conditions that affect the respiratory system, which includes the organs and structures involved in breathing. Inhalation CDMOs are used in the development and manufacturing of products for respiratory disorders due to their expertise in formulating and delivering drugs to the lungs, offering specialized expertise, infrastructure, and resources to pharmaceutical companies seeking to bring innovative inhalation therapies. For instance, in June 2023, according to reports shared by the Australian Institute of Health and Welfare, an Australia-based national agency, there was a rise in respiratory disease-related deaths from 43,031 in 2020 to 46,551 in 2021in Australia. Furthermore, in September 2022, according to the data published by The Lancet, a UK-based book and periodic data publishing organization, 11,255 new cases of RSV were recorded in 2021, which is 11.4% more compared to 9,972 cases in 2020. Therefore, the increasing prevalence of respiratory disorders is driving the growth of the inhalation CDMO market.

Key Industry Players

Major companies operating in the inhalation cdmo market report are Pfizer Inc., Merck KGaA, Baxter’s BioPharma Solutions, Lonza Group AG, Catalent Inc., AptarGroup Inc., Samsung Biologics Co. Ltd., Siegfried Holding AG, Recipharm AB, Stevanato Group SpA, Cambrex Corporation, CordenPharma, Nemera, Hovione FarmaCiencia SA, Vectura Group Ltd., CARBOGEN AMCIS, Kindeva Drug Delivery Ltd., Frontage Laboratories Inc, Formosa Laboratories Inc, Sanner GmbH, H&T Presspart Ltd., Astech Projects Ltd, Cliantha Research, Dipharma Francis Srl, Copley Scientific

The inhalation cdmo market report table of contents includes: